Ocumension Therapeutics
01477
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
552
Stocks News & Analysis
stocks
Why stocks sometimes fall for no obvious reason
How the private markets impact all equity investors.
stocks
Poor organic growth obscured by acquisition for ASX listed share
Sales dropped by 2% without impact of acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,865.30 | 26.90 | -0.30% |
| CAC 40 | 8,086.00 | 31.42 | -0.39% |
| DAX 40 | 24,606.77 | 130.47 | -0.53% |
| Dow JONES (US) | 50,285.66 | 276.31 | 0.55% |
| FTSE 100 | 10,443.47 | 11.13 | 0.11% |
| HKSE | 25,686.41 | 299.89 | 1.18% |
| NASDAQ | 26,293.10 | 22.74 | 0.09% |
| Nikkei 225 | 63,359.11 | 1,674.97 | 2.72% |
| NZX 50 Index | 12,991.31 | 113.24 | 0.88% |
| S&P 500 | 7,445.72 | 12.75 | 0.17% |
| S&P/ASX 200 | 8,646.20 | 25.90 | -0.30% |
| SSE Composite Index | 4,109.48 | 32.21 | 0.79% |